MedTrace Logo

Incorporating the Venous Excess Ultrasound Score (VExUS Score) Into Contemporary Haemodynamic Risk Assessment in Pulmonary Arterial Hypertension: The INVEXUS-PAH Study

NCT07266012 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 86

Last updated 2025-12-15

No results posted yet for this study

Summary

This prospective observational study aims to evaluate the relationship between the Venous Excess Ultrasound Score (VEXUS) and the ESC/ERS 2022 simplified four-strata risk assessment model in adult patients with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH). The study investigates whether VEXUS can enhance risk stratification and predict haemodynamic congestion by correlating VEXUS with functional, biochemical, and invasive haemodynamic parameters.

Conditions

  • Pulmonary Arterial Hypertension (PAH)
  • Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)

Sponsors & Collaborators

  • Istanbul University - Cerrahpasa

    lead OTHER

Principal Investigators

  • SAHRA ASENA BALCIOGLU, MD · ISTANBUL UNIVERSITY-CERRAHPASA INSTITUTE OF CARDIOLOGY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-07
Primary Completion
2025-11-05
Completion
2025-11-21

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07266012 on ClinicalTrials.gov